Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PTCT
HOLDPTC Therapeutics, Inc. · Healthcare · United States · $6.4B · Avg Vol: $169M/d
COMPANY DESCRIPTION
PTC Therapeutics, Inc. is a U.S. biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with rare diseases. The company specializes in RNA-focused science and has a portfolio of approved drugs and a robust pipeline targeting genetic disorders such as Duchenne muscular dystrophy and AADC deficiency. Its pioneering work in rare disease treatment and global commercial infrastructure provide a strong position in a high-need therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 698.8M | 937.8M | 806.8M | 1.7B | 35.3% | 827.1M | 1.2B | 1.3B | -11.9% |
| EPS | -7.79 | -8.37 | -4.73 | 8.58 | — | -2.54 | — | — | — |
| Shares | 73.1M | 75.7M | 77.7M | 81.5M | +11.4% | 82.9M | — | — | — |
| Debt | 1.5B | 2.2B | 2.5B | 2.7B | 22.8% | 2.7B | — | — | — |
| Equity | -347.1M | -818.6M | -1.1B | -205.3M | — | — | — | — | — |
| Op CF | -356.7M | -158.4M | -107.7M | 711.2M | — | -217.9M | — | — | — |
| Inv CF | 290.2M | -176.7M | 44.2M | -862.0M | — | — | — | — | — |
| Fin CF | 168.0M | 646.4M | 255.9M | 331.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PTCT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PTCT | PTC Therapeutics, Inc.(you) | $6.4B | 45 | HOLD |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.9B | 47 | HOLD |
| 0HKF.L | Axsome Therapeutics, Inc. | $7.7B | 45 | HOLD |
| TVTX | Travere Therapeutics, Inc. | $5.3B | 48 | HOLD |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $8.4B | 47 | HOLD |
| DFTX | Definium Therapeutics, Inc. | $5.7B | 38 | HOLD |
| BLTE | Belite Bio, Inc | $6.1B | 37 | HOLD |
| IMVT | Immunovant, Inc. | $8.1B | 40 | HOLD |
| PTGX | Protagonist Therapeutics, Inc. | $8.8B | 50 | HOLD |
| ELVN | Enliven Therapeutics, Inc. | $3.8B | 44 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%